Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Accession Requirements for ICH Assembly Hammered Out at Fukuoka Confab
June 12, 2015
-
ORGANIZATION EFPIA Japan Chief Frets Negative Market Growth amid Pressure on Drug Costs
June 11, 2015
-
BUSINESS Novartis Japan Chief Vows All-Out Effort to Regain Trust
June 10, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 5: Lackluster 1% Sales Growth Likely in FY2015
June 10, 2015
-
REGULATORY LDP Eyes Filing of 15 Sakigake Designated Products by FY2018
June 9, 2015
-
ORGANIZATION Industry, Govt, Academia Should Discuss Challenges Facing Biosimilars: Prof. Kurokawa
June 9, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 4: Overseas Sales Top 4 Trillion Yen; Fate of Drug Makers Will Depend on New Global Products
June 9, 2015
-
REGULATORY Roughly 60 Products Submitted as Candidates for Review under Sakigake Designation System
June 8, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 3: New Cancer Drugs Off to Strong Start
June 8, 2015
-
BUSINESS Lilly Japan Plans Excursion to Local Cities in Quest for Novel Drug Seeds
June 5, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 2: Sales of 42 Major Long-Listed Products Sag Nearly 20%
June 5, 2015
-
ORGANIZATION PhRMA Chairman Says Budget Issues Controllable with Generics
June 4, 2015
-
BUSINESS Highlights of FY2014 Earnings - Part 1: 35 Listed Drug Makers See Downtrend in Profits Despite 3% Sales Uptick
June 4, 2015
-
ACADEMIA Pfizer Poised to Emerge as Global Leader in Oncology: Chief Medical Officer
June 3, 2015
-
REGULATORY MHLW Stands by “80% in FY2020” as New Generic Use Target, Says It’s “Barely Reachable”
June 2, 2015
-
REGULATORY MOF Panel Recommends Generic Target of 80% by FY2017-End
June 2, 2015
-
REGULATORY AMED Hopes to Create Fund to Nurture Researchers through Contributions from Drug Makers: President Suematsu
June 1, 2015
-
ORGANIZATION Doctors Need to Be More Cost-Conscious When Prescribing: Dr Imamura of JMA
May 29, 2015
-
REGULATORY MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015
-
ORGANIZATION FPMAJ, JPMA, and JGA Call for “Balanced” Approach to Control Drug Expenditure in Joint Declaration
May 28, 2015
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…